Antibodies against human platelet alloantigens and human leucocyte antigen class 1 in Saudi Arabian multiparous women and multi-transfused patients

Abstract

Objectives:To determine the frequency of alloimmunization against human platelet antigens (HPAs) and human leucocyte antigen class 1 (HLA1) in multiparous women and multi-transfused patients.Methods:This prospective study was conducted between January and August 2013, on 50 multiparous women with no history of previous blood transfusion recruited from the Obstetrics and Gynecology Clinic, and 50 patients, who received multiple platelet transfusions, recruited from the Hematology/Oncology Ward, King Khalid University Hospital, Riyadh, Saudi Arabia.Results:The frequency of alloimmunization among multiparous pregnant women was 76%, as follows: 16% against HLA1 only, 8% against HPAs only, 52% against both HPAs and HLA1 antigens. In multi-transfused patients, the rate of alloimmunization was 42% as follows: 2% against HLA1 only, 22% against HPAs only, 18% against both HPAs and HLA1 antigens. The frequency of alloimmunization increases with the number of pregnancies, but not with the number of platelet transfusions.Conclusion:Alloimmunization against HPAs and HLA1 is very common among Saudi multiparous women and multi-transfused patients, which encourages the search for the extent of the possible complications in the fetus and newborn and in multitransfused patients and how to prevent their occurrence.

Analysis of platelet‐reactive alloantibodies and evaluation of cross‐match‐compatible platelets for the management of patients with transfusion refractoriness

“…Anti‐HLA class I antibodies causing PTR is a common and serious complication of alloimmunised patients receiving long‐term platelet transfusions (Cid et al ., ). In this study, the rate of alloimmunisation was 114 of 204 (55.88%), which was close to that of many earlier publications (Table ) (Economidou et al ., ; Friedman et al ., ; Kurz et al ., ; Ferreira et al ., ; Al‐Ouda et al, ), including 112 of 114 (98.25%) caused by anti‐HLA class I antibodies. As most of platelet transfusion refractory patients had haematological diseases, we showed that the antibody‐positive rate was significantly different between the haematological disease group and the other disease group.…”

“…Austria (Kurz et al, 1996) 54.00 -Saudi Arabia (Al-Ouda et al, 2015) 42.00 2-124 (43.75%) and anti-HLA-C07 (25.00%), which is consistent with our previous study that described the most common HLA-A and HLA-B alleles in our donor registry (Xia et al, 2010). In light of the findings presented, this study demonstrates that if the patient has HLA Class I antibodies to high-frequency antigens, it is increasingly difficult for them to receive suitable platelet units through cross-match assays.…”